Search results
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 2 days agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
UPDATE 3-Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Reuters via Yahoo Finance· 2 days ago(Adds details on Eylea sales miss in paragraph 2, consensus estimates for Eylea 8mg in paragraph 5) May 2 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall ...
Regeneron records mixed results for Q1 as Eylea revenues fall
Crain's New York Business· 2 days agoThe slight dip was driven by decreases in sales of one eye disease drug, Eylea. While Schott predicted that the macular degeneration therapy would bring in $2.2 billion in sales, the medication ...
EYLEA HD shows promise in long-term clinical trials By Investing.com
Investing.com· 5 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) today revealed positive long-term...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks· 2 days agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics ...
Regeneron: Q1 Earnings Snapshot
San Francisco Chronicle· 2 days agoTARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN)...
Checking in on Regeneron Pharmaceuticals, Inc.
Knox Daily· 3 days agoRegeneron Pharmaceuticals, Inc.’s filing revealed that its EVP Commercial McCourt Marion unloaded Company’s shares for reported $0.24 million on Apr 01 ’24. In the deal valued ...
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
Morningstar· 2 days agoBy Denny Jacob Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S. The biotechnology ...
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Pharmaceutical Technology via Yahoo Finance· 3 days agoThis news stands in contrast to Regeneron’s greatly anticipated high-dose EYLEA (EYLEA...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenge
Guru Focus· 2 days agoRevenue: Reported at $3.15 billion, a decrease of 1% year-over-year, falling short of estimates of $3.22 billion.Net Income: GAAP net income reached $722 milli
